Rare Disease Report

3rd Annual Sickle Cell Disease Therapeutics Conference

SEPTEMBER 03, 2014
RDR Staff

On September 15, 2014, the 3rd Annual Sickle Cell Disease Therapeutics Conference will be held at the Cosmopolitan Suite of the Four Seasons Hotel in New York City, NY.  Hosted by Mast Therapeutics, the day-long event will include many scientific, regulatory, clinical, investment, and advocacy leaders discussing the advances and concerns within the sickle cell community.

Speakers will include Althea Grant, Ph.D. (CDC),  Nicole Verdun, M.D.  (FDA),  and Sonja L. Banks (Sickle Cell Disease Association of America), as well as clinical trial/drug development updates from Mast Therapeutics, Daiichi Sankyo, Eli Lilly, Glycomimetics,  Prolong Pharmaceuticals,  and bluebird bio.  There will also be panel discussions with patients, healthcare analysts and investors.

Below is the schedule of events

8:00 – 8:30am      
8:30 – 8:35am      
Welcome Ioana C. Hone (Hone Group Inc.)
8:35 – 8:45am      
Opening Remarks Brian M. Culley (Mast Therapeutics)
8:45 – 9:15am      
Sickle Cell Disease Overview Althea Grant, Ph.D. (CDC)
9:15 – 10:05am    
Patient Panel Edward A. Tenthoff (Piper Jaffray & Co.) with Kristyl J. L. Smith (SCD patient) and Tanya Gentry (San Diego Chapter of SCDAA)
10:05 – 10:55am  
Physician Panel Ritu S. Baral (Cowen & Co.) with Julie Kanter-Washko, M.D. (Medical University of South Carolina) and Kathryn L. Hassell, M.D. (University of Denver)
10:55 – 11:00am  
11:00 – 11:30am  
Keynote Presentation - SCD Patient-Focused Drug Development Meeting Highlights Nicole Verdun, M.D. (FDA. CDER - Division of Hematology Products)
11:30 – 11:45pm  
VOICE Crisis Alert™ Introduction Oluwatosin Ola (Mast Therapeutics, Inc.)
11:45 – 11:55am 
The Pierre Fabre Foundation Presenting Sponsor
11:55 – 1:00pm   
1:00 – 1:35pm     
Healthcare Analyst-Led Investor Panel John Newman (Canaccord Genuity) with Carl L. Gordon, Ph.D., CFA (Partner, OrbiMed Advisors LLC)
1:35 – 1:40pm     
Overview of Drug Development Brian M. Culley (Mast Therapeutics, Inc.)
1:40 – 2:05pm     
bluebird bio Richard Smith, VP Investor Relations
2:10 – 2:35pm     
Daiichi Sankyo, Inc. / Eli Lilly & Co. Joseph A. Jakubowski, Ph.D., Senior Clinical Research Fellow
2:40 – 3:05pm     
GlycoMimetics, Inc. Rachel King, President & CEO
3:10 – 3:35pm     
Mast Therapeutics, Brian M. Culley, CEO
3:40 – 4:05pm     
Prolong Pharmaceuticals, LLC Glenn Kazo, President
4:10 – 4:35pm     
Living Differently With Sickle Cell Disease – Patient Perspectives Brenda Ochieng (SCD Patient, HbF), Lisa M. Rose (Executive Director, HOPE for SCD), a failed BMT experience (patient TBA)
4:40 – 4:55pm     
The Importance of the Community Based Organization Sonja L. Banks, President & COO (Sickle Cell Disease Association of America, Inc.)
4:55 – 5:00pm     
Closing Remarks

The conference is free to all persons who pre-register.  For additional details, visit www.SCDconference.com.

Image of sickle cell blood smear courtesy wikimedia commons.

Stay informed on the latest rare disease news and developments by signing up for our newsletter.
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.